skip to Main Content

Germline Testing At Diagnosis Vital for Managing Pancreatic Cancers

Newsfeed image, light gray text on dark gray background
Clinical trials for patients with pancreatic cancer have begun to offer an array of therapies that target certain mutations. There are also several FDA-approved targeted therapies for these patients.

With all of these available options, Elena G. Chiorean, MD, stated that patients should undergo genetic testing at the time to diagnosis, during a presentation for the 17th Annual Meeting of the International Society of Gastrointestinal Oncology (ISGIO 2020). Read more . . . 

 


Back To Top